RTP Mobile Logo
Year in Review: Clinical Investigators Provide Perspectives on the Most Relevant New Publications, Data Sets and Advances in Lymphomas (Faculty Presentations)
Released March 2021

Featuring slide presentations and related discussion from Drs Christopher R Flowers and Sonali M Smith. (Video Program)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of lymphomas.


    • Appreciate the FDA approval of rituximab/lenalidomide for the management of relapsed/refractory (R/R) follicular lymphoma (FL) and available Phase III data investigating its use as front-line therapy, and optimally incorporate this novel therapeutic approach into current treatment algorithms.
    • Recognize the recent FDA approval of tazemetostat for R/R FL, and identify patients for whom treatment with this novel agent may be appropriate.
    • Describe the biologic rationale for, available data with and current clinical role of BTK (Bruton tyrosine kinase) inhibitors for patients with R/R mantle cell lymphoma (MCL), and discern how these agents can be appropriately and safely integrated into routine practice.
    • Assess the FDA-approved indication for selinexor for patients with R/R diffuse large B-cell lymphoma (DLBCL) after at least 2 prior therapies, and consider how this agent can be appropriately and safely incorporated into clinical management algorithms.
    • Understand the mechanism of action of tafasitamab, and appreciate available research data documenting the efficacy and safety of this novel anti-CD19 antibody in combination with lenalidomide for patients with R/R DLBCL.
    • Review available efficacy and safety data with chimeric antigen receptor T-cell therapies directed at CD19, and identify patients with R/R large cell lymphomas for whom this approach may be appropriate.
    • Consider clinical, biologic and patient-related factors in the selection of first-line therapy for newly diagnosed classical Hodgkin Lymphoma (HL).
    • Develop a personalized long-term care plan for patients with R/R HL, considering prior exposure to systemic therapy, eligibility for transplant, symptomatology, performance status and goals for treatment.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Christopher R Flowers, MD, MS
    Chair, Professor
    Department of Lymphoma/Myeloma
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene, Celgene Corporation, Denovo Biopharma, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, MEI Pharma Inc, Pharmacyclics LLC, an AbbVie Company, Spectrum Pharmaceuticals Inc; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas, Celgene Corporation, Eastern Cooperative Oncology Group, Genentech, a member of the Roche Group, Gilead Sciences Inc, Janssen Biotech Inc, National Cancer Institute, Pharmacyclics LLC, an AbbVie Company, Takeda Oncology, TG Therapeutics Inc, V Foundation for Cancer Research.

    Sonali M Smith, MD
    Elwood V Jensen Professor of Medicine
    Interim Chief, Section of Hematology/Oncology
    Co-Leader, Cancer Service Line
    Director, Lymphoma Program
    The University of Chicago
    Chicago, Illinois

    Consulting Agreements: Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, MorphoSys, TG Therapeutics Inc; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Celgene Corporation, Epizyme Inc, Forty Seven Inc, Genentech, a member of the Roche Group, Karyopharm Therapeutics, Novartis, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, TG Therapeutics Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Epizyme Inc, Incyte Corporation, Karyopharm Therapeutics, Novartis, Pharmacyclics LLC, An AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Seagen Inc.

    Release date: March 2021
    Expiration date: March 2022

Acknowledge and close

Watch video
(WIFI is recommended for best performance):